InvestorsHub Logo
Followers 198
Posts 24247
Boards Moderated 0
Alias Born 04/03/2010

Re: JerryCampbell post# 397100

Friday, 08/20/2021 3:24:21 PM

Friday, August 20, 2021 3:24:21 PM

Post# of 681852
They continue to get patents and develop the technology, pushing it further and further along, so that is not entirely true. Plus we do not know what they have discussed with regulators along the way. It is a huge potential platform, and it is ready to take forward. I suspect it will be perceived as quite similar and likely less risky and less processed than DCVax-L, and in fact, as I recall, likely to qualify as a non-engineered cell therapy. While DCVax-L is not engineered either it does take steps exposing the cells taken out to the tumor lysate.

I suspect, the hurdles may be less than anticipated for a variety of reasons, once they have cash flow and that they may seek to develop DCVax-L and DCVax Direct on a parallel path, the primary difference being lysate vs non-lysate prior to administration, and then mode of administration. I think the regulators are getting more sophisticated on this stuff every year and it is a moving target as to what you might need to do, and starting too early might literally be a risk too, engaging complexities and complications that might have otherwise been avoided.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News